Comprehensive diagnostic, prognostic, and predictive testing
Oncology testing is rapidly advancing—from new technology and discoveries in molecular biomarkers to emerging therapies. Mayo Clinic Laboratories innovates at the speed of medical advancement, and offers comprehensive options for diagnostic, prognostic, and predictive lung cancer testing.
Guiding treatment selection
Lung cancer treatment options are selected based on
molecular test results, and proper treatment selection directly impacts patient outcomes. Selecting the most appropriate treatment, whether standard, off-label, or clinical trials, begins
with high-quality molecular testing.
Providing results for more patients
Accurate results are the first step to timely, effective, and
efficient patient care. Unlike other laboratories, our specimen
requirements are optimized to conserve tissue, which makes
results available for more patients.
Interpretation by Mayo Clinic experts
Your results are interpreted by Mayo Clinic physicians with
expertise in pulmonary oncology. Each report integrates
patient information with supporting references. This provides
patient-specific context and a better understanding of the
treatment path ahead.
Update on 2015 WHO classification of lung adenocarcinoma
Most patients with lung cancer present at advanced stage and cannot be treated by surgical resection. Alternative treatment options are needed. Subtyping of lung cancer is very important because of advances in the identification of genetic abnormalities that allow for a more targeted approach in a subset of patients.
AJCC 8th edition of lung cancer staging: emphasis on multiple lung carcinomas
This “Specialty Testing” webinar, presented by Marie Christine Aubry, M.D., discusses changes introduced in the 8th edition of the AJCC lung cancer staging manual.